Known targets — ChEMBL curated mechanism
PPARDPTGS1PTGS2dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Lysine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 2/20 | 0.87 |
| ▸ | ARG2 | P78540 | 4/20 | 0.53 |
| ▸ | ARG1 | P05089 | 3/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.52 |
| ▸ | GRM8 | O00222 | 1/20 | 0.52 |
| ▸ | GRM6 | O15303 | 1/20 | 0.52 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.52 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.52 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.52 |
| ▸ | GRM5 | P41594 | 1/20 | 0.52 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.52 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.52 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.52 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.52 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.52 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.52 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.52 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.52 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.52 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lysine SCHEMBL1000738 | 1.00 | GSR (0.87) | GSRARG2ARG1CYP1A2GRM8 | |
| Lysine SCHEMBL4583369 | 1.00 | GSR (0.87) | GSRARG2ARG1CYP1A2GRM8 | |
| Lysine SCHEMBL845918 | 1.00 | GSR (0.87) | GSRARG2ARG1CYP1A2GRM8 | |
| Lysine SCHEMBL209698 | 1.00 | GSR (0.87) | GSRARG2ARG1CYP1A2GRM8 | |
| Lysine SCHEMBL209697 | 1.00 | GSR (0.87) | GSRARG2ARG1CYP1A2GRM8 | |
| Lysine SCHEMBL23295178 | 1.00 | GSR (0.87) | GSRARG2ARG1CYP1A2GRM8 | |
| Lysine SCHEMBL2182542 | 1.00 | GSR (0.87) | GSRARG2ARG1CYP1A2GRM8 | |
| Lysine SCHEMBL377041 | 1.00 | GSR (0.87) | GSRARG2ARG1CYP1A2GRM8 | |
| Lysine SCHEMBL7082500 | 0.98 | GSR (0.83) | GSRARG2ARG1CYP1A2GRM8 | |
| Lysine SCHEMBL8950821 | 0.94 | GSR (0.77) | GSRARG2ARG1CYP1A2GRM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024140917-A1 | ANTI-CD40 ANTIBODY-DRUG CONJUGATE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 上海盛迪医药有限公司 | 2024-07-04 | — | — | WO | claimed |
| EP-4374879-A1 | DRUG CONJUGATE OF ERIBULIN DERIVATIVE | Shanghai Senhui Medicine Co., Ltd. (CN) | 2024-05-29 | — | — | EP | claimed |
| CN-117510829-A | Nitrogen-branched polyethylene glycol derivative containing amino acid residue | 厦门赛诺邦格生物科技股份有限公司 | 2024-02-06 | — | — | CN | claimed |
| WO-2024022237-A1 | THREE-ARM POLYETHYLENE GLYCOL DERIVATIVE CONTAINING AMINO ACID RESIDUES | 厦门赛诺邦格生物科技股份有限公司 | 2024-02-01 | — | — | WO | claimed |
| WO-2023143351-A1 | DRUG CONJUGATE OF GLUCOCORTICOID | 上海盛迪医药有限公司 | 2023-08-03 | — | — | WO | claimed |
| WO-2023124963-A1 | ANTIBODY-DRUG CONJUGATE HAVING REDUCED REVERSIBLE REACTION, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 昆山新蕴达生物科技有限公司 | 2023-07-06 | — | — | WO | claimed |
| EP-4190812-A1 | ANTI-CD79B ANTIBODY-DRUG CONJUGATE, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | Tuojie Biotech (Shanghai) Co., Ltd. (CN) | 2023-06-07 | — | — | EP | claimed |
| WO-2023061466-A1 | PREPARATION METHOD FOR ERIBULIN DERIVATIVE | 江苏恒瑞医药股份有限公司 | 2023-04-20 | — | — | WO | claimed |
| WO-2021148003-A1 | DRUG CONJUGATE OF ERIBULIN DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF IN MEDICINE | 上海森辉医药有限公司 | 2021-07-29 | — | — | WO | claimed |
| WO-2024140917-A1 | ANTI-CD40 ANTIBODY-DRUG CONJUGATE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 上海盛迪医药有限公司 | 2024-07-04 | — | — | WO | disclosed |
| EP-4374879-A1 | DRUG CONJUGATE OF ERIBULIN DERIVATIVE | Shanghai Senhui Medicine Co., Ltd. (CN) | 2024-05-29 | — | — | EP | disclosed |
| EP-4365219-A1 | ASPARTIC ACID COMPOSITION, POLYSUCCINIMIDE COMPOSITION, POLYASPARTIC ACID COMPOSITION, AND CROSS-LINKED POLYASPARTIC ACID COMPOSITION | DIC Corporation (JP) | 2024-05-08 | — | — | EP | disclosed |
| CN-117642453-A | Aspartic acid composition, polysuccinimide composition, polyaspartic acid composition, and crosslinked polyaspartic acid composition | DIC株式会社 | 2024-03-01 | — | — | CN | disclosed |
| CN-117510829-A | Nitrogen-branched polyethylene glycol derivative containing amino acid residue | 厦门赛诺邦格生物科技股份有限公司 | 2024-02-06 | — | — | CN | disclosed |
| US-20050153876-A1 | Compositions of lipopeptide antibiotic derivatives and methods of use thereof | MIGENIX INC. (CA) | 2005-07-14 | — | — | US | disclosed |
| WO-2005000878-A2 | COMPOSITIONS OF LIPOPEPTIDE ANTIBIOTIC DERIVATIVES AND METHODS OF USE THEREOF | MIGENIX INC. (CA) | 2005-01-06 | — | — | WO | disclosed |
| EP-1242365-A1 | ACYL PSEUDODIPEPTIDES WHICH CARRY A FUNCTIONALISED AUXILIARY ARM | OM Pharma (CH) | 2002-09-25 | — | — | EP | disclosed |
| WO-2001046126-A1 | ACYL PSEUDODIPEPTIDES WHICH CARRY A FUNCTIONALISED AUXILIARY ARM | OM PHARMA (CH) | 2001-06-28 | — | — | WO | disclosed |
| US-4448715-A | Tagged pyroglu-L-Phe-L-Arg derivatives, substrates and assays for kallikrein | UNIVERSITY OF MIAMI (US) | 1984-05-15 | — | — | US | disclosed |
| US-4056519-A | TRIPEPTIDYL-4-METHOXY-2-NAPHTHYLAMIDE | ELI LILLY AND COMPANY (US) | 1977-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050153876-A1 | Compositions of lipopeptide antibiotic derivatives and methods of use thereof | NRDC, NOD2, NGLY1 | GSR 3380/4885ARG2 2160/4885ARG1 1476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.